Multi-functional nanocarriers to overcome tumor drug resistance

被引:361
作者
Jabr-Milane, Lara S. [1 ]
van Vlerken, Lilian E. [1 ]
Yadav, Sunita [1 ]
Amiji, Mansoor M. [1 ]
机构
[1] Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA
关键词
Multi-drug resistance; Multi-functional nanocarriers; Drug delivery; Resistance modulators; Energy delivery;
D O I
10.1016/j.ctrv.2008.04.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The development of resistance to variety of chemotherapeutic agents is one of the major challenges in effective cancer treatment. Tumor cells are able to generate a multi-drug resistance (MDR) phenotype due to microenvironmental selection pressures. This review addresses the use of nanotechnology-based delivery systems to overcome MDR in solid tumors. Our own work along with evidence from the literature illustrates the development of various types of engineered nanocarriers; specifically designed to enhance tumor-targeted delivery through passive and active targeting strategies. Additionally, multi-functional nanocarriers are developed to enhance drug delivery and overcome MDR by either simultaneous or sequential delivery of resistance modulators (e.g., with P-glycoprotein substrates), agents that regulate intracellular pH, agents that tower the apoptotic threshold (e.g., with ceramide), or in combination with energy delivery (e.g., sound, heat, and tight) to enhance the effectiveness of anticancer agents in refractory tumors. In preclinical studies, the use of multi-functional nanocarriers has shown significant promise in enhancing cancer therapy, especially against MDR tumors. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:592 / 602
页数:11
相关论文
共 84 条
[1]  
BELL EL, 2007, ANTIOXID REDOX S NOV
[2]  
Brizel DM, 1996, CANCER RES, V56, P941
[3]   TUMOR HYPOXIA, DRUG-RESISTANCE, AND METASTASES [J].
BROWN, JM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (05) :338-339
[4]   Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells [J].
Buys, Timon P. H. ;
Chari, Raj ;
Lee, Eric H. L. ;
Zhang, May ;
MacAulay, Calum ;
Lam, Stephen ;
Lam, Wan L. ;
Ling, Victor .
GENES CHROMOSOMES & CANCER, 2007, 46 (12) :1069-1079
[5]   Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment [J].
Cairns, R ;
Papandreou, I ;
Denko, N .
MOLECULAR CANCER RESEARCH, 2006, 4 (02) :61-70
[6]   ABCB1 pharmacogenetics:: Progress, pitfalls, and promise [J].
Chinn, L. W. ;
Kroetz, D. L. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (02) :265-269
[7]  
Comerford KM, 2002, CANCER RES, V62, P3387
[8]   Molecular prognostic markers in breast cancer [J].
Dahiya, R ;
Deng, GR .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) :185-200
[9]   Role of ABC transporters in the chemoresistance of human gliomas [J].
Decleves, Xavier ;
Amiel, Alexandra ;
Delattre, Jean-Yves ;
Scherrmann, Jean-Michel .
CURRENT CANCER DRUG TARGETS, 2006, 6 (05) :433-445
[10]   Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model [J].
Devalapally, Harikrishna ;
Shenoy, Dinesh ;
Little, Steven ;
Langer, Robert ;
Amiji, Mansoor .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (04) :477-484